August 2, 2025

Supplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

View Full Paper

Ask AI

Bookmark

Azenosertib effectively inhibits WEE1 kinase, demonstrating broad antitumor activity across different solid tumors.
Optimized dosing schedules have been proposed based on enhancements in the efficacy of azenosertib treatment.
The study involves investigating the intermittent dosing schedule for azenosertib in various cancer models.
Findings contribute to understanding how azenosertib can be utilized for better cancer treatment outcomes.

Implication

Supplementary figure shows that azenosertib, a WEE1 kinase inhibitor, improves antitumor activity in solid tumors, suggesting effective dosing strategies.

Abstract

Supplementary Figure S5. Additional optimization of azenosertib intermittent dosing schedule

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ma et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d020e https://doi.org/10.1158/1535-7163.29760439

View Full Paper

Ask AI

Bookmark

Implication

Supplementary figure shows that azenosertib, a WEE1 kinase inhibitor, improves antitumor activity in solid tumors, suggesting effective dosing strategies.

Abstract

Supplementary Figure S5. Additional optimization of azenosertib intermittent dosing schedule

Supplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading